SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
4.550
-0.170 (-3.60%)
At close: Oct 1, 2026, 4:00 PM EDT
4.547
-0.003 (-0.06%)
After-hours: Oct 1, 2026, 7:30 PM EDT
SciSparc Revenue
In the year 2025, SciSparc had annual revenue of $856.00K, down -34.46%. SciSparc had revenue of $856.00K in the quarter ending December 31, 2025, a decrease of -34.46%.
Revenue (ttm)
$856.00K
Revenue Growth
-34.46%
P/S Ratio
2.32
Revenue / Employee
$380,000
Employees
3
Market Cap
2.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 856.00K | -450.00K | -34.46% |
| Dec 31, 2024 | 1.31M | -1.57M | -54.64% |
| Dec 31, 2023 | 2.88M | 1.53M | 113.73% |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.72M |
| PMGC Holdings | 2.58M |
| GeoVax Labs | 852.28K |
| Onconetix | 645.82K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 102.81K |
| Silo Pharma | 54.08K |
| Valion Bio | -86.00K |
SPRC News
- 8 days ago - SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine - TheFly
- 8 days ago - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - GlobeNewsWire
- 4 weeks ago - SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 4 weeks ago - SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 4 weeks ago - SciSparc subsidiary provides update on SCI-210 trial enrollment - TheFly
- 4 weeks ago - SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - GlobeNewsWire
- 4 weeks ago - NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - TheNewswire
- 4 weeks ago - Neurothera Labs Inc. Announces Share Consolidation - TheNewswire